Lytix Biopharma – Licensing partner Verrica Pharmaceuticals announces pricing of underwritten public offering, raising approximately USD 42 million upon completion November 21, 2024
Ellos Group announces completion of refinancing milestone – bondholders become new owners and liquidity financing is underwritten September 24, 2024
